Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
- None.
- None.
Insights
Advancements in liquid biopsy technology, such as the introduction of Twist Bioscience's cfDNA Library Preparation Kit, represent a significant step forward in the field of oncology research. The ability to detect rare tumor variants from degraded and low-input samples is crucial for early cancer detection and personalized treatment plans. This technology enhances the sensitivity and accuracy of liquid biopsies, which are non-invasive alternatives to traditional tissue biopsies. The high conversion rates mentioned imply an improved ability to detect low-frequency variants, which can be vital for early intervention and monitoring of minimal residual disease (MRD). The development of such kits can potentially lead to more effective cancer management strategies and could have a positive impact on patient outcomes.
From a market perspective, the launch of the cfDNA Library Preparation Kit by Twist Bioscience aligns with the growing demand for non-invasive diagnostic methods, such as liquid biopsies. The liquid biopsy market is experiencing rapid growth due to its application in early detection and monitoring of various cancers. Twist Bioscience's addition to its product portfolio could increase its competitiveness in the precision medicine industry. The kit's ability to integrate with existing target enrichment systems and custom capture panels may encourage adoption among researchers and healthcare providers. This innovation could contribute to the company's market share growth and potentially influence its stock valuation positively if adopted widely.
The clinical implications of the Twist cfDNA Library Preparation Kit are significant for oncologists and their patients. The kit's high accuracy and detection rates for tumor variants are essential for the application of liquid biopsy in cancer screening and treatment. By enabling the detection of variants that are often missed by other library preparation solutions, the kit provides a more comprehensive profile of a patient's cancer. This can inform more personalized treatment plans and may lead to better patient outcomes. Furthermore, the ability to detect minimal residual disease with greater sensitivity is a critical advantage in the monitoring of cancer recurrence. The ease of integration with other Twist products could streamline research and clinical workflows, potentially expediting the adoption of liquid biopsy techniques in clinical settings.
High accuracy and detection to identify tumor variants from degraded and low input samples as well as samples with limited DNA abundance
Library preparation kit adds to Twist’s portfolio of tools to enable liquid biopsy applications
Liquid biopsies have gained prominence in critical applications such as cancer screening, including multi-cancer early detection screening and monitoring for minimal residual disease (MRD). Liquid biopsy tests are designed to accurately identify tumor variants within circulating tumor DNA (ctDNA), which are often difficult to detect due to degraded or limited DNA presence. The Twist cfDNA Library Preparation Kit was purpose-built to maximize the number of unique cfDNA molecules that are captured in library preparation, for higher confidence in the accuracy and sensitivity of liquid biopsy tests.
“Liquid biopsies can be life changing for patients, enabling earlier detection of cancer and profiling each patient’s unique tumor to inform personalized treatment plans,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Even with advancements in the sensitivity of tests that have enabled the liquid biopsy field to expand, some tumor variants remain incredibly difficult for researchers to detect in the earlier stages of disease. With exceptional accuracy and sensitivity enabled by high conversion rates, the Twist cfDNA Library Preparation Kit can help push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions.”
The Twist cfDNA Library Preparation Kit adds to Twist’s growing portfolio of tools to support the research and development of liquid biopsy assays, which also includes the recently launched Twist cfDNA Pan-Cancer Reference Standard v2. The reference standards are a tool for researchers to use in the development and quality monitoring of clinically relevant variants for developing NGS-based assays. The updated reference standards include one of the industry-leading numbers of circulating tumor DNA (ctDNA) variants and clean background cfDNA for a significantly lower background error rate. The reference standards can be seamlessly integrated into Twist’s suite of target enrichment systems and custom capture panels.
Twist cfDNA Library Preparation Kit
The Twist cfDNA Library Preparation Kit can address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input. It can detect even rare allele variants due to its high conversion rate. The cfDNA kit protocols minimize sample handling for a streamlined workflow and results delivered within two hours. The Twist cfDNA Library Preparation Kits are available in two configurations: the cfDNA Library Preparation Kit for whole genome sequencing (WGS) workflows and the Twist Library Preparation and Hyb Mix Kit for target enrichment.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist cfDNA Library Preparation Kit to maximize the number of unique cfDNA molecules that are captured in library preparation, push the limit of detection and detect lower frequency variants that can be missed by other on market library preparation solutions, address challenges associated with library preparation from circulating cfDNA with reliable and robust performance from as little as 1ng sample input, and detect rare allele variants. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 2, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206958346/en/
For Investors:
Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com
For Media:
Amanda Houlihan
Communications Manager
774-265-5334
ahoulihan@twistbioscience.com
Source: Twist Bioscience Corporation
FAQ
What is Twist Bioscience Corporation's (TWST) latest product launch?
What are the key features of the Twist cfDNA Library Preparation Kit?
What are the applications of liquid biopsies in cancer screening?
How does the Twist cfDNA Library Preparation Kit contribute to liquid biopsy research?
What are the available configurations of the Twist cfDNA Library Preparation Kit?
